Ivosidenib as Post-HSCT Maintenance for AML

This is a Phase 2 study of the study drug, ivosidenib (a mutant IDH1 inhibitor), compared to placebo, given to patients with IDH1-mutant acute myeloid leukemia (AML) after hematopoietic stem cell transplantation (HCT).

Trial Details

NCT ID
NCT06707493
Phase
PHASE2
Sponsor
Massachusetts General Hospital
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Ivosidenib
  • Placebo
Locations (sample)
  • Atlanta, Georgia, United States|33.749,-84.38798
  • Kansas City, Kansas, United States|39.11417,-94.62746
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Columbus, Ohio, United States|39.96118,-82.99879

Key Eligibility Criteria

  • Pathologically confirmed diagnosis of IDH1(R132)-mutant acute myeloid leukemia (AML). IDH1 mutations could have been detected by any mutational tec…
  • Between the ages of 18 and 75 years
  • Will undergo allogeneic hematopoietic stem cell transplantation (HSCT) for their malignancy. Conditioning may be either conventional myeloablative …
  • ECOG performance status ≤ 2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →